Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study

Massimo Iavarone, Federica Invernizzi, Tommy Ivanics, Stefano Mazza, Claudio Zavaglia, Marco Sanduzzi‐Zamparelli, Miguel Fraile‐López, Carolin Czauderna, Giovanni Di Costanzo, Sherrie Bhoori, Matthias Pinter, Matteo Angelo Manini, Giuliana Amaddeo, Ainhoa Fernandez Yunquera, Federico Piñero, Maria Jose Blanco Rodríguez, Margarita Anders, Gabriel Aballay Soteras, Gerda Elisabeth Villadsen, Peter Daechul Yoon, Lucia Cesarini, Álvaro Díaz‐González, Maria Luisa González‐Diéguez, Raffaella Tortora, Arndt Weinmann, Vincenzo Mazzaferro, Mario Romero Cristóbal, Gonzalo Crespo, Helene Regnault, Mass

Distinct Hepatic Gene‐Expression Patterns of NAFLD in Patients With Obesity

Sonu Subudhi, Hannah K. Drescher, Laura E. Dichtel, Lea M. Bartsch, Raymond T. Chung, Matthew M. Hutter, Denise W. Gee, Ozanan R. Meireles, Elan R. Witkowski, Louis Gelrud, Ricard Masia, Stephanie A. Osganian, Jenna L. Gustafson, Steve Rwema, Miriam A. Bredella, Sangeeta N. Bhatia, Andrew Warren, Karen K. Miller, Georg M. Lauer, Kathleen E. Corey – 10 August 2021 – Approaches to manage nonalcoholic fatty liver disease (NAFLD) are limited by an incomplete understanding of disease pathogenesis.

Subscribe to